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A Novel Motor, KIF13A, Transports Mannose-6-
Phosphate Receptor to Plasma Membrane through
Direct Interaction with AP-1 Complex
that bind KIFs to transporting vesicles. Transmembrane
receptors or some membrane-bound proteins have
been postulated to bind KIFs to cargo vesicles. Kinectin,
a transmembrane protein on the ER membrane that in-
teracts directly with conventional kinesin (KIF5B), is a
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On the other hand, studies on protein targeting areJapan
‡The Institute of Physical and Chemical Research carried out from the side of transmembrane proteins
that are actually being targeted. It is established that(RIKEN)
Saitama 351-0198 adaptor and scaffolding proteins bind to the cytoplasmic
domain of the transmembrane proteins to mediate pro-Japan
tein targeting (Pearse, 1988; Rongo et al., 1998). Scaf-
folding proteins seem to function both in selective reten-
tion of the targeted protein and in the initial step of
vesicle formation and trafficking. General adaptor com-Summary
plex AP-1 functions by recognizing the tyrosine-based
and dileucine-based cytoplasmic signals of membraneIntracellular transport mediated by kinesin superfam-
ily proteins (KIFs) is a highly regulated process. The proteins to recruit them into the newly formed clathrin-
coated buds at TGN. Likewise, it is well established thatmolecular mechanism of KIFs binding to their respec-
tive cargoes remains unclear. We report that KIF13A other adaptors (AP-2, AP-3, and AP-4) also participate
in protein targeting of membrane proteins between dif-is a novel plus end-directed microtubule-dependent
motor protein and associates with b1-adaptin, a sub- ferent membrane compartments (Pearse, 1988; Dell’
Angelica et al., 1997; Bonifacino and Dell’Angelica, 1999;unit of the AP-1 adaptor complex. The cargo vesicles
of KIF13A contained AP-1 and mannnose-6-phosphate Hirst et al., 1999). Newly formed membrane buds, whose
cytoplasmic surfaces are covered with coat proteinsreceptor (M6PR). Overexpression of KIF13A resulted in
mislocalization of the AP-1 and the M6PR. Functional and adaptor proteins, are loaded with cargo membrane
proteins. Then, vesicles are formed by budding off and,blockade of KIF13A reduced cell surface expression of
the M6PR. Thus, KIF13A transports M6PR-containing presumably, transferred to the microtubule-dependent
transport machinery as mediated by molecular motors.vesicles and targets the M6PR from TGN to the plasma
membrane via direct interaction with the AP-1 adaptor However, the link has been missing between these
adaptor proteins and vesicle transport, particularly withcomplex.
the microtubule-dependent molecular motors.
This study elucidates the missing link between theIntroduction
AP-1 adaptor complex and the microtubule-dependent
molecular motor by proving that KIF13A binds directlyCell morphology and polarity are accomplished by pro-
tein targeting. Molecular motors of the kinesin super- to the AP-1 complex. The function of this interaction
during membrane transport was studied using an epi-family proteins (KIFs) are among the force-generating
vehicle enzymes that function in the intracellular delivery thelial cell system where AP-1 is known to function via
two distinct transport pathways, i.e., TGN to plasmamachinery (Hirokawa, 1996, 1998). Membrane proteins
are posttranslationally modified at the Golgi apparatus membrane (AP-1B) and TGN to endosomes (AP-1A)
(Folsch, et al., 1999). Our results suggest that the interac-and are targeted to their appropriate destination in the
form of small transporting vesicles. These vesicles are tion between KIF13A and b1-adaptin functions in AP-
1B-dependent membrane protein targeting from TGN togenerated by budding off from the trans-Golgi network
(TGN) and are further carried via the microtubule-based the plasma membrane.
transport machinery (Sciaky et al., 1997; Cole et al.,
1998; Nakata et al., 1998; Presley et al., 1998). Appar- Results
ently, KIFs are involved in the vesicle transport from
TGN, but the molecular mechanism underlying the spe- Characteristics of KIF13A Protein
cific recognition of cargo vesicles by KIFs and the selec- The motor domain of a novel motor KIF13A was identi-
tive targeting of transported vesicles to their appropriate fied by intensive PCR homology cloning. Its function was
destination remain unclarified. suggested to be in fundamental intracellular transport
Attempts have been made to search for molecules processes based on several lines of evidence (Naka-
gawa et al., 1997). First, the expression of KIF13A in
an adult mouse is ubiquitous and is not restricted to§ To whom correspondence should be addressed (e-mail: hirokawa@
m.u-tokyo.ac.jp). proliferating tissues such as the spleen and testis, sug-
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Figure 1. KIF13A Protein Is a Ubiquitous Molecular Motor for Vesicle Transport
(A) Domain structure of novel motor KIF13A. The motor domain is in the amino terminal. The calculated molecular weight and pI were 195.8
kDa and 5.12, respectively.
(B) Diagonal plot to compare homology between KIF13A and KIF1A. Identity in the motor domain is 60%.
(C) SDS-PAGE result of the purification process of KIF13A-HS. TH 5 total homogenates; CE 5 crude extract; FT 5 flowthrough of the crude
extract after application to the metal affinity chelating column. Elution was performed stepwise with increasing concentrations of imidazole
(from 50 mM to 500 mM). The prominent band of 200 kDa is recombinant KIF13A. The molecular weights (MW) are 200, 116, 97, 66, and 45
kDa from the top of the gel.
(D) Ubiquitous expression of KIF13A protein in developing brain and other tissues. 20 mg of brain lysate was loaded in each lane in SDS-
PAGE. Western blotting was performed by anti-KIF13A polyclonal antibody. The molecular weights (MW) standards are the same as in (C).
(E) Expression of KIF13A protein in subregions of the 4-week-old mouse nervous system. 20 mg of protein was loaded in each lane. The lanes
are those of proteins from the olfactory bulb, hippocampus, cerebral cortex, inferior colliculus, superior colliculus, amygdala, putamen,
cerebellum, pons, medulla, spinal cord, and sciatic nerve from the left.
(F) Subcellular fractionation of the 4-week-old mouse brain monitored for KIF13A. The pellet fraction is concentrated ten times in this experiment.
KIF13A is present in the membrane pellet fraction as well as in the high-speed supernatant.
(G) Nycodenz density gradient subcellular fractionation. The S1 fraction in Figure 2D was subjected to Nycodenz density gradient to confirm
that KIF13A in P2 and P3 is bound to vesicles. Membranous material that has a lower density than the soluble protein floated toward the top
of the tube. KIF13A was resolved in two peaks (soluble and membrane-bound). When nonionic detergent NP-40 was applied prior to the
density gradient, the membrane-associated KIF13A peak disappeared.
(H) Gel filtration of recombinant and native KIF13A. Collected fractions were analyzed by Western blotting using an anti-KIF13A antibody.
Note that recombinant KIF13A and native KIF13A were eluted in different fractions.
(I) Analysis of gel filtration. Relative values obtained from the Western blotting data (H) were plotted (AU 5 arbitrary unit). Fraction and elution
volumes (ml) are indicated. Molecular weight markers used were thyroglobulin 5 669 kDa, ferritin 5 440 kDa, and catalase 5 232 kDa.
Recombinant and native elution peaks were identical to catalase and ferritin, respectively.
(J) The AMP-PNP-dependent absorption of KIF13A to microtubules and release by ATP in the brain lysate. See text for procedures. Each
fraction was separated by SDS-PAGE and blotted with anti-KIF13A and -KIF5B (experimental control). The amount of tubulin was monitored
to confirm microtubule polymerization (CBB staining).
(K) Motility assay of KIF13A recombinant. Microtubule bundles from Clamydomonas flagella move towards minus-ends of microtubules on
recombinant KIF13A-coated coverslip. Scale bar is 0.1 mm. Two ends of the microtubule bundle are indicated.
gesting the possibility that KIF13A is more important in of the KIFs that is phylogenetically distant from KIFs
functioning in cell division.intracellular transport than in mitotic cell division. Sec-
ond, the molecule is evolutionarily conserved from C. The full-length cDNA of KIF13A was cloned. KIF13A
consists of 1749 amino acids with its motor domainelegans to mammals. Third, KIF13A is a new member
KIF13A Transport M6PR through Interaction with AP-1
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Figure 2. KIF13A Forms Complex with AP-1 via Direct Interaction with b1-Adaptin
(A) Recombinant GST fusion proteins used to affinity-purify proteins that bind to KIF13A tail domain. The number indicates the amino acid
(aa) number of KIF13A. CTF stands for carboxyl terminal fragment.
(B) Results of GST pull-down experiments. The CBB staining of the gel used in SDS-PAGE (7.5% gel) is shown. Lanes 1 and 4 resolve the
proteins attached to the beads before incubating with the brain lysate. The migration positions of the fusion proteins, GST-CTF1 and GST-
CTF2, are indicated in the right. p110 is the protein that is specifically coeluted with the GST-CTF2 protein but not with the GST-CTF1 protein.
(C) Western blotting results of immunoprecipitation experiments are shown. Each lane corresponds to the immunoprecipitates obtained using
the following antibodies: lane 1 5 control mouse IgG (ten times the amount of IgG used for b1-adaptin monoclonal antibody); lane 2 5 1/10
of the amount of antibody used in lane 1; lane 3 5 anti-b-adaptin; lane 4 5 rabbit pre-immune IgG of anti-KIF13A antibody; lane 5 5 anti-
KIF13A antibody (affinity-purified).
(D) In vitro binding of purified recombinant KIF13A and b1-adaptin. The CBB staining result of the SDS-PAGE is shown. The following proteins
were incubated and immunoprecipitated using an anti-KIF13A antibody and resolved by SDS-PAGE. KIF13A alone (lane 1), GST alone (lane
2), KIF13A and GST (lane 3), GST alone (lane 4), KIF13A and GST (lane 5), GST- b1-adaptin alone (lane 6), and KIF13A and GST- b1-adaptin
(lane 7). In lanes 2 and 3, ten times the amount of GST used for lanes 4 and 5 was used for protein incubation. Color of arrows: red 5 KIF13A;
blue 5 GST- b1-adaptin; and yellow 5 IgG. The molecular weights (MW) are 200, 116, 97, 66, 45, and 31 kDa from the top of the gel.
(E) Yeast two-hybrid assay. Eight different deletion constructs of b1-adaptin were tested for their interaction ability with KIF13A. The number
in the bracket of each deletion mutant indicates the amino acid number of b1-adaptin. KIF13A and b1-adaptin deletion constructs were
cotransformed into yeasts. The transformants were plated onto SC plates (lacking luecine, tryptophane, and uracil) and X-gal plates (lacking
histidine, tryptophane, uracil, and leucine).
(F) Proteins in the brain lysate that were bound to the GST-CTF2 column were eluted with reduced glutathione. Elution fractions (lanes 2–6)
were resolved by SDS-PAGE, and Western blotting was performed using antibodies against subunits of the AP-1 complex (anti-b1,2-adaptin,
anti-g-adaptin, and anti-m1-adaptin antibodies). In lane 1, the input brain lysate applied onto the column was Western blotted with an anti-
b1,2-adaptin antibody. In the input, b2-adaptin was more abundant than b1-adaptin. In the elution fraction, b1-adaptin was specifically eluted.
Moreover, subunits of the AP-1 complex coeluted from the column.
(G) The peak elution fraction in F (described as purified b-1 and purified m-1 in the figure) was further fractionated by 5%–30% (wt/vol) linear
sucrose velocity gradient centrifugation. To compare the S values with native AP-1 in the brain lysate, brain-high-speed supernatant was also
fractionated. Purified b1-adaptin (the band that was peptide-sequenced) was detected by CBB staining. Other subunits were detected by
Western blotting. Purified AP-1 complex and native AP-1 formed different peaks. The positions of marker proteins are indicated above. 4.3S
(BSA), 11.1S (catalase), and 16.5S (thyroglobulin).
(H) Densitometric analysis of sucrose velocity gradient centrifugation. Native AP-1 in brain lysate was 7.7S, whereas purified AP-1 was 8.9S.
The difference in the S values can be explained because the KIF13A tail domain (GST-CTF2) is bound to the purified AP-1 in the column
eluate.
(I) KIF13A binds to the ear domain of b1-adaptin. To determine the specificity of binding, a GST pull-down experiment was performed in the
brain lysate using ear domains of b1- and b2-adaptin as probes. GST was used as a control probe. Brain lysate was incubated with an equal
amount of probes (GST, GSTb1-ear domain, and GSTb2-ear domain). Proteins bound to each probe were resolved by SDS-PAGE and Western
blotted using an anti-KIF13A antibody. The CBB staining result of the applied probes is shown in the lower panel.
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Figure 3. Subcellular Localization of KIF13A and the Cargo Vesicles
(A–C) L cells were stained with preimmune IgG (A) and anti-KIF13A antibodies (B). 3T3 cells are stained in (C). The perinuclear region is
strongly stained but with a weaker cytoplasmic staining.
(D–I) NRK cells were double stained with an anti-KIF13A polyclonal antibody (green, [D]) and a Golgi apparatus marker CTR433 monoclonal
antibody (red, [E]). Partial overlap is observed between KIF13A and CTR433 (F). JG-I; NRK cells were double stained using an anti-rab6
polyclonal antibody and an anti-AP-1 monoclonal antibody. Partial overlap was observed between rab6 and AP-1. Scale bar is 50 mm.
(J) Western blotting detected AP-1 in vesicles affinity-purified using KIF13A tail domain.
(K) Immunoelectron microscopy observation of KIF13A in 3T3 cells. 3T3 cells were fixed with a PLP fixative. Intracellular KIF13A was detected
using an anti-KIF13A polyclonal antibody followed with biotin-avidin-peroxidase system. KIF13A was particularly detected on the Golgi
apparatus and vesicles in the cytoplasm (arrows in [K]). The right panel indicates the control stained with preimmune IgG. M 5 mitochondria,
N 5 nucleus, and G 5 Golgi apparatus.
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in the amino terminal (Figure 1A). An AF6/cno domain tubules in the presence of 0.5 mM AMP-PNP. When the
microtubules were ultracentrifuged, most of KIF5B (the(Ponting, 1995) exists, which is also observed in KIF1
family members. The function of this domain is unknown. conventional kinesin) was absorbed to the microtubules
and the pellet (lane 2), while KIF13A was equally distrib-No other domains were detected by the motif search.
The full sequence is available in GenBank (accession uted in the pellet and supernatant (lanes 1 and 2). On
incubating the resuspended microtubules pellet in 5 mM#AB037923). The homology between KIF13A and KIF1A
(the most related KIF by molecular phylogenetic analy- ATP, ATP-dependent release of KIF13A was observed
(lanes 3 and 4). KIF5B and tubulin were monitored assis) is plotted in Figure 1B. The putative cargo binding
domain at the carboxyl terminal is different between the experimental controls.
Motor activity was assayed by differential interferencetwo molecules. Recombinant KIF13A (Figure 1C) and
synthetic peptides were used to generate polyclonal contrast microscopy and video system. KIF13A was a
fast plus-end directed microtubule-dependent molecu-antibodies in rabbits. The KIF13A antibody recognized
a 200 kDa protein in the brain lysate by Western blotting lar motor, and could slide axonemes in a microtubule
minus-end direction (Figure 1K). The average velocity(calculated molecular weight 5 195.8 kDa). Both KIF13A
mRNA (Nakagawa et al., 1997) and the protein were was 0.1–0.3 mm/s, which indicates that KIF13A can func-
tion as a motor for fast intracellular transport.observed to be ubiquitously distributed in tissues (Fig-
ure 1D). A weak cross-reactivity at 116 kDa was detected Altogether, KIF13A has the characteristics of a vesi-
cle-transporting microtubule-dependent motor protein.in the testis and PC12 cell. The identity of this 116 kDa
protein was not determined. KIF13A was also expressed
in most subregions of the nervous system (Figure 1E). Tail Domain of KIF13A Forms a Complex
with b1-AdaptinKIF13A was recovered from both the soluble and the
membrane fractions by differential centrifuge cell frac- The nonmotor domain of KIF13A (the tail domain) is
expected to bind to a specific cargo. To identify proteinstionation (Figure 1F). Brain lysates were fractionated by
a Nycodenz density gradient flotation assay to confirm binding to KIF13A from the mouse brain, the tail domain
of KIF13A fused to GST was immobilized to a columnthe existence of KIF13A on vesicles (Figure 1G). KIF13A
was detected as two peaks, a soluble peak and a vesi- to perform affinity chromatography. Two GST fusion
constructs, GST-CTF1 and GST-CTF2 (Figure 2A), werecle-bound peak. When the lysate was treated with NP-40
before being subjected to the Nycodenz density gradi- used. The 110 kDa band (p110) was specifically copuri-
fied with GST-CTF2 beads, not with GST-CTF1 beadsent assay, the vesicle-bound KIF13A peak disappeared.
This suggests that KIF13A is associated with NP-40 (Figure 2B). Amino acid sequencing revealed that p110
is b1-adaptin, a subunit of the AP-1 complex (Zarembasoluble vesicles.
To determine whether KIF13A exists as a dimeric mo- and Keen, 1983; Ahle et al., 1988; Gallusser and Kirch-
hausen, 1993). The KIF13A and b1-adaptin were coim-tor with two catalytic motor domains or as a monomer
such as KIF1A (Okada and Hirokawa, 1999), the molecu- munoprecipitated as a protein complex from the mouse
brain lysate using either anti-KIF13A or anti-b1-adaptinlar weight of the native KIF13A in the brain lysate and
purified recombinant KIF13A was compared by gel filtra- antibodies (Figure 2C). Furthermore, purified recombi-
nant KIF13A expressed in the baculovirus-insect celltion (Figures 1H and 1I). The native KIF13A was eluted
from the fraction of approximately 440 kDa, whereas system and purified recombinant GST-b1-adaptin ex-
pressed in E. coli were demonstrated to bind to eachrecombinant KIF13A was eluted from the fraction of
approximately 200 kDa. The data suggest that KIF13A other in vitro in a specific manner (Figure 2D).
exists in the native form either as a homodimer or a
monomer associated with some protein. Because the Ear Domain of b1-Adaptin Interacts with Carboxyl
Terminal of KIF13Amicrotubule-gliding motility was observed in the purified
recombinant KIF13A as mentioned below, KIF13A itself The molecular structures of adaptins have been exten-
sively studied (Gallusser and Kirchhausen, 1993; Orci etis sufficient for the motility. Purification of the native
KIF13A is necessary to determine the precise molecular al., 1993; Shih et al., 1995; Wilde and Brodsky, 1996).
b1-adaptin is composed of three domains: trunk, hinge,component of the KIF13A complex.
AMP-PNP-dependent microtubule binding and the and ear domains (Figure 2E). The trunk domain interacts
with another major subunit of the AP-1 complex, g-adap-release from microtubules mediated by ATP were exam-
ined for native KIF13A (Figure 1J). Brain high-speed su- tin. The hinge domain can interact with clathrin. The
binding partner of the ear domain is unknown.pernatant was incubated with Taxol-polymerized micro-
(L–Q) EM images of vesicles affinity-purified by the KIF13A tail domain CTF2. Vesicles were specifically purified by incubating the vesicle
fraction with beads coated with CTF2 ([L]–[P], arrow heads) but not with control beads coated with CTF1 (Q). The mean numbers of vesicles
purified per bead were 28 for CTF2 and 0.6 for CTF1, n 5 5. The vesicles were 50–80 nm in diameter. Note that the vesicles do not have
distinguishable clathrin coats. Scale bar 5 500 nm (for all EM data).
(R–W) To evaluate the existence of AP-1 on vesicles that can bind KIF13A, vesicles were affinity-purified on glass-coated cover using the
AP-1 binding domain of KIF13A (GST-CTF2 fragment). Vesicles were specifically purified with the GST-CTF2 (R), not with the GST-CTF1
control protein (S). Vesicles observed in a 100 mm2 field were counted and the results are shown as a histogram (T). Bar 5 SEM, n 5 4.
Vesicles were stained with anti-g-adaptin to detect AP-1 on the tethered vesicles on the cover glass. Immunofluorescence observations are
shown in (V) and (W). DIC image (U), fluorescent image (V), and merged image (W). The green proportion in each histogram (T) is the amount
of AP-1 positive vesicles. 40% of vesicles that were bound to GST-CTF2 were AP-1 positive.
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Figure 4. Overexpression of KIF13A Results in AP-1 Redistribution
(A–F) When KIF13A was overexpressed, the subcellular distribution of AP-1 changed drastically. Cells overexpressing KIF13A are highlighted
in (A) and (D) (detected using a polyclonal anti-KIF13A antibody). The normal Golgi distribution of AP-1 was reduced significantly and AP-1
was redistributed to the tip of the processes when KIF13A was overexpressed (B and E). Intense overlap staining was observed at the tip of
the processes ([C and F], arrows). Colocalization and accumulation of KIF13A and AP-1 were observed at the tip of the processes ([C and
F], arrows). L cells (mislocalization phenotype observed in 91%, n 5 137) and MDCK cells (89%, n 5 104) are shown. Similar results were
obtained with other cell lines such as 3T3, NRK, and Vero cells.
(G–R) To exclude the artifacts such as disruption of subcellular membrane compartments, we examined the Golgi apparatus (anti-rab6, [H]),
trans-Golgi network (monoclonal anti-GalT antibody, i.e., b1–4 galactosyltransferase, [K]), ER (PDI monoclonal antibody, [Q]), and endosomes
(polyclonal anti-cathepsin D, [N]) in cells overexpressing KIF13A. None of these subcellular compartments were disrupted by KIF13A overexpres-
sion. KIF13A overexpressing cells are highlighted in (G), (J), (M), and (P) (detected by either a 9E10 monoclonal antibody or polyclonal anti-
KIF13A antibody). Merged images are shown in (I), (L), (O), and (R). Scale bar is 50 mm.
To identify the binding domain of b1-adaptin with AP-1 Complex Is Copurified with KIF13A
Tail DomainKIF13A tail domain, we used the yeast two-hybrid inter-
action assay (Figure 2E). Only the full-length b1-adaptin b1-adaptin is a subunit of the tetrameric protein com-
plex, AP-1 (major b1 and g subunits, and minor m1 andand fusion proteins that contained the ear domain inter-
acted with the KIF13A tail domain. Thus, the ear domain s1 subunits). In TGN, AP-1 binds to clathrin to enhance
the clathrin-coat assembly at the newly formed clathrin-of b1-adaptin is responsible for the interaction with
KIF13A. coated buds. AP-1 interacts with the cytoplasmic do-
KIF13A Transport M6PR through Interaction with AP-1
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main of the membrane proteins and recruits them to the CTR433 and polyclonal antibody against rab6 (Martinez
et al., 1994) (Figures 3G–3I). The intracellular localizationnewly formed clathrin-coated buds. We further deter-
mined whether KIF13A can bind to b1-adaptin in the of KIF13A was further determined by immunoelectron
microscopy. The KIF13A was specifically detected onform of the AP-1 complex.
The eluate from the GST-CTF2 column was examined, membranes, particularly on the Golgi apparatus and
vesicles (Figure 3K). The ultrastructural subcellular lo-in detail, by Western blotting with other subunits of the
AP-1. Both g-adaptin and m1-adaptin were coeluted with calization of KIF13A is consistent with its biochemical
interaction with AP-1.b1-adaptin (Figure 2F). The peak fraction was further
fractionated by sucrose velocity gradient centrifugation
(Figure 2G). b1-, g-, and m1-adaptin existed in the same
KIF13A Tail Domain Purifies Clathrin-Coat-Negativefractions, supporting that these proteins form a com-
AP-1-Containing Vesiclesplex. The size of the complex was determined to be 8.9
The vesicle fractions of the Nycodenz density gradientS by sucrose velocity gradient centrifugation (Figure 2H).
centrifugation were incubated with beads coated withThe S value of the purified AP-1 in complex with the
the KIF13A tail domain (GST-CTF2). Western blottingKIF13A tail was slightly larger than the endogenous AP-1
detected AP-1 on this purified vesicle fraction (Figurecomplex in the cytosol (7.7 S). Collectively, we conclude
3J). Increase in clathrin amount was not observed com-that KIF13A binds to the AP-1 complex by directly inter-
pared with the control by Western blotting (data notacting with the b1-adaptin subunit.
shown).
The purified cargo vesicles were further determined
Interaction of KIF13A with AP-1 Is Specific In Vitro
by EM observation (Figures 3L–3Q). The vesicles did not
AP-1 (b1, g, m1, s1 subunits) and AP-2 (b2, a, m2, s2
have any morphologically recognizable clathrin coats,
subunits) are highly related molecules that differ in func-
consistent with the Western blotting. They were 50–80
tion (Ahle et al., 1988; Pearse, 1988; Schroder and Un-
nm in diameter. They form a class of the smallest vesi-
gewickell, 1991). AP-1 functions in vesicle trafficking
cles thus far determined as cargoes of motor proteins.
from the TGN to the endosome and the plasma mem-
The authenticity of the isolated vesicles was confirmed
brane, whereas AP-2 functions in vesicle trafficking from
by the immuno-EM observation, which detects KIF13A
the plasma membrane to the endosomes (Pearse, 1988).
antigens on vesicles that are similar in size (Figure 3K).
In most cells, the polarity of radiating microtubules is
We evaluated if AP-1 actually exists on vesicles that
such that the minus-ends are directed toward the MTOC
can bind KIF13A. Vesicles were affinity-purified with the
where the Golgi apparatus exists and the plus-ends are
KIF13A tail domain attached to a solid support (cover
directed toward the cell periphery. AP-1 should be on
glass) and further visualized by immunofluorescence mi-
the vesicles that move toward the plus-ends, and AP-2
croscopy (vesicle tethering assay on cover glass).
toward the minus-ends. Thus, it is likely that AP-2 and
The presence of AP-1 on the vesicles isolated by
AP-1 are associated with different motors.
KIF13A tail was visualized by staining the tethered vesi-
We determined whether KIF13A interacts only with
cles on the cover glass with an anti-AP-1 monoclonal
AP-1 or with both AP-1 and AP-2. The KIF13A tail domain
antibody (Figures 3R–3W). Approximately 40% of the
copurifies more b1-adaptin than b2-adaptin from the
vesicles that were specifically tethered by the KIF13A
brain lysate (Figure 2F). When GST pull-down was per-
tail domain were AP-1 positive, whereas less than 10%
formed with GST (control), the GST-b1-adaptin ear do-
of the vesicles that were tethered by control protein
main, and the GST-b2-adaptin ear domain as probes,
(CTF1 fragment) were AP-1 positive (Figure 3T).
KIF13A was copurified more with the b1-adaptin ear
Thus, AP-1 is present but the clathrin coat is absent
domain than with the b2-adaptin ear domain (Figure 2I).
on vesicles that can bind to the KIF13A tail domain. This
Thus, KIF13A binds to b1-adaptin with higher affinity
suggests that clathrin-coated vesicles formed in TGN are
than to b2 in vitro.
uncoated during KIF13A-dependent vesicle transport.
Subcellular Distribution of KIF13A Partially
Overlaps with AP-1 Overexpression of KIF13A Alters Subcellular
Localization of AP-1Subcellular localization of KIF13A was determined by
immunofluorescence confocal microscopy. KIF13A are If KIF13A carries AP-1, overexpression of KIF13A may
alter the subcellular localization of AP-1. We transfectedlocalized mainly at perinuclear regions in L cells (Figures
3A and 3B), 3T3 cells (Figure 3C), and NRK cells (Figures myc-epitope-tagged KIF13A in L cells, Vero cells, and
MDCK cells. In cells overexpressing KIF13A, perinuclear3D–3F). The perinuclear pattern showed partial overlap-
ping with the Golgi apparatus marker CTR433 (Jasmin localization of AP-1 was lost and a strong immunoreac-
tivity was observed in the cell periphery, especially atet al., 1989), suggesting that KIF13A may function in
vesicle trafficking from the Golgi. Double staining of the tip of the long extending processes (Figures 4A–4F,
arrow). The Golgi apparatus itself was morphologicallycultured cells with anti-KIF13A and anti-AP-1 antibodies
was attempted, but because of the incompatibility of intact as monitored by rab6 (Golgi Marker; Martinez et
al., 1994) and GalT (TGN marker: b1–4galactsyltrans-the fixation conditions between the two antibodies, it
was technically unsuccessful. As an alternative ap- ferase) (Kawano et al., 1994; Figures 4G–4L). Further-
more, to exclude the possible redistribution of knownproach, we demonstrated the association between
KIF13A and AP-1 by demonstrating the presence of both membrane compartments, membrane markers for en-
dosomes (cathepsin D) and ER (PDI) were examined inmolecules in the Golgi by double labeling each molecule
with Golgi markers such as a monoclonal antibody the cells overexpressing KIF13A (Figures 4M–4R). None
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Figure 5. Overexpression of KIF13A Results in Mannose-6-Phosphate Receptor Redistribution
M6PR staining of MDCKII cells transfected with KIF13A (A and D). In some cases accumulation of M6PR, together with KIF13A, was observed
at the cell periphery (A, B, and C). (C) is a merge of (A) and (B), (F) is a merge of (D) and (E). Note that perinuclear staining of M6PR disappears
in cells overexpressing KIF13A (C and F). KIF13A overexpressing cells are highlighted in (B) and (E). Only one cell is observed to overexpress
KIF13A in (B) and (E). The arrows indicate the processes extending from the overexpressing cell in the center of Figure 5B. N indicates the
position of the nucleus of the transfected cells. Scale bar is 50 mm.
(G) Western blotting results of immunoprecipitation are shown. b-adaptin, g-adaptin, and M6PR were coprecipitated with an anti-KIF13A
antibody, (lane 2) not with a preimmune IgG (lane 1).
of these membrane markers exhibited abnormal distri- zymes at the Golgi apparatus and shuttles them to the
prelysosomal compartment, where the receptor and en-bution when KIF13A was overexpressed.
Moreover, taking into account the polarity of microtu- zyme-ligands are dissociated in an acidic environment.
M6PR also functions at the cell surface where extracellu-bules in these cells, the direction of AP-1 translocation
was consistent with the direction of movement observed lar soluble ligands with M6P recognition signals, such
as insulin-like growth factor II (IGF-II), are bound andby the in vitro motility assay data (Figure 1K).
internalized by endocytosis. M6PR is involved in the
turn over of the external soluble ligands rather than inAP-1 and Mannose-6-Phosphate Receptor
Coprecipitate with KIF13A the signal transduction mediated by the other receptors.
Indeed, after binding to the M6PR, IGF-II is further de-in the Membrane Fraction
The mannose-6-phophate receptor (M6PR) can exit TGN graded by lysosomes.
Intracellular trafficking of M6PR has been well studied.by interacting with AP-1 in clathrin-coated vesicles.
M6PR binds to mannose-6-phosphate (M6P) recogni- Direct interaction between M6PR and AP-1 has been
established (Pearse, 1985). AP-1 has a dual functiontion signals on the newly synthesized lysosomal en-
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Figure 6. Translocation of M6PR Is KIF13A-
Specific
Overexpression of KIF5B (A, B, and C), KIF1A
(D, E, and F), and KIF13A that was deleted in
the AP-1 binding domain (G, H, and I) in
MDCKII cells. M6PR was not mislocalized fol-
lowing overexpression of either KIF5B (nor-
mal localization phenotype observed in 83%,
n 5 113), KIF1A (85%, n 5 95), or deleted
KIF13A (85%, n 5 89). (B), (E), and (H) are
M6PR staining. Overexpressed cells are high-
lighted in (A), KIF5B, detected by an H2
monoclonal antibody; (D), KIF1A, detected by
a GFP tag; and (G), KIF13A tail deleted, de-
tected by 9E10. Scale bar is 50 mm.
of recruiting clathrin coat to the newly formed vesicle- between KIF13A and AP-1 in vivo, we established MDCK
cell lines that stably express the AP-1 binding domainprecursor buds at TGN and further sequestering recep-
tors into these clathrin-coated buds. When the Triton of KIF13A. Cell-surface M6PR expression in a nonpolar-
ized state was monitored by flow cytometry. DominantX-100-solubilized membrane fraction was immunopre-
cipitated with an anti-KIF13A antibody, both AP-1 and negative proteins were tagged with GFP to monitor the
level of intracellular expression. Reduction in the ex-M6PR were detected in the immunoprecipitate (Figure
5G). This result suggests that KIF13A, b1-adaptin, and pression level of cell surface M6PR was observed in
stable MDCK cell lines that express the GFP-KIF13A tailM6PR can form a complex on vesicle.
domain but not in control cell lines that express the GFP
or GFP-KIF1A tail domain (Figure 7A, left histograms,Overexpression of KIF13A Alters Subcellular
red lines). The expression of each dominant negativeLocalization of Mannose-6-Phosphate Receptor
protein was also confirmed by Western blotting (FigureIn cells overexpressing KIF13A, both AP-1 and M6PR
7B). The expression level of the GFP-KIF13A tail waswere mistargeted (Figures 4A–4F and 5A–5F). The nor-
proportional to the reduction of that of cell-surfacemal TGN profile of M6PR was lost by overexpression of
M6PR (Figures 7A and 7B; compare clones 2 and 9).KIF13A. When KIF13A accumulated at high levels in the
The total expression of M6PR (the sum of cell surfacecell periphery, M6PR was also detected (Figures 5A–5C,
and intracellular expression) was unchanged per a sin-arrows). Intracellular localization of M6PR is influenced
gle cell of the different cell lines as determined by West-by the amount of the molecular motor, KIF13A. Overex-
ern blotting (Figure 7B). Thus, the dominant negativepression of other motors such as KIF1A and KIF5B that
GFP-KIF13A tail domain that contains the entire AP-1are known to function in vesicle transport (Figures 6A–
binding site particularly reduced the M6PR surface ex-6F) had no effect. In addition, KIF13A without the AP-1
pression. The result is consistent with our proposedbinding domain was also overexpressed as a control
function of KIF13A in targeting vesicles that containexperiment (Figures 6G–6I). None of these control exper-
M6PR.iments mistargeted M6PR (Figures 6A–6I).
None of the membrane compartments were disorga-
nized by overexpressing KIF13A (Figures 4G–4R). Thus, Discussion
overexpression of KIF13A specifically redistributes AP-1
and M6PR, suggesting that both AP-1 and M6PR are AP-1 Is a Motor Adaptor as well as a Coat Adaptor
transported by KIF13A. We identified a novel motor KIF13A that interacts di-
rectly with the b1 subunit of a general adaptor, AP-1.
Our study demonstrates the molecular mechanism byFunctional Blockade of KIF13A by Dominant
Negative Protein Reduces M6PR Expression which KIF interacts with the membrane. The function of
AP-1 is to bind to the transmembrane receptors (forLevels on the Cell Surface
AP-1 functions in protein targeting from the TGN to the example, mannose-6-phosphate receptor) (Pearse, 1988)
and enhance recruitment of clathrin coat to induce for-plasma membrane in MDCK cells (Folsch et al., 1999). To
investigate the functional significance of the interaction mation of clathrin-coated vesicles in the TGN. The orien-
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tation of AP-1 relative to the membrane is such that the
trunk domains of the b1 and g subunits are directed
toward the membrane, whereas the ear domains extend
away from the membrane (Haar et al., 1998; Musacchio
et al., 1999). The KIF13A tail domain interacts with the
ear domain. Spatially, the ear domain is the most distant
domain from the membrane and is easily accessible for
KIF13A. We propose that AP-1 functions as a motor
adaptor, as well as a coat adaptor.
Redundancy between KIF and Cargo
Specificity and redundancy are observed between KIFs
and their cargo vesicles. Specificity is demonstrated by
the absence of the KIF3 complex and KIF5B on the
vesicles immunoisolated using a KIF1A antibody (Okada
et al., 1995). Two types of redundancy exist between
the cargo and the motor: a single motor carrying two
different types of cargoes (as in the case of KIF5B, where
transport of both mitochondria and lysosomes is defec-
tive in KIF5B null mutant cells) (Tanaka et al., 1998), and
two different motors carrying a single organelle (as in
the case of mitochondria being carried by both KIF1B
and KIF5B) (Nangaku et al., 1994; Tanaka et al., 1998).
The indirect nature of association between KIF13A
and the membrane via AP-1 is a possible explanation
for the redundancy. Different receptors can be trans-
ported by KIF13A because redundancy exists between
AP-1 and various membrane receptors (Pearse, 1988).
Moreover, the indirect nature of interaction between
KIFs and receptors also explains the possible multiregu-
latory nature of vesicle transport. When fluorescent-
labeled vesicles are visualized in cultured viable neu-
rons, a complex behavior, such as back-and-forth
movement and fission, is observed, suggesting a multi-
regulatory mechanism (Nakata et al., 1998).
KIF13A Transports Mannose-6-Phosphate Receptor
The transport of receptor molecules by a particular KIF
has been demonstrated by an indirect method such
as colocalization and vesicle immunoaffinity purification
strategy. The phenotypes of loss-of-function or null mu-
tants of KIFs in C. elegans, Drosophila, and mouse are
related to accumulation or mislocalization of certain
membrane proteins or organelles. The precise molecular
mechanism of association between membrane recep-
tors and other components of the vesicle such as cy-
tively. The red histograms are cell surface M6PR expression of the
indicated stable cell lines. In the right column, the histograms of
nontransfected cells are indicated in black, whereas the GFP ex-
pression of the control GFP cell line is indicated in green. The GFP
level of the stable transformants that express the GFP-dominant
Figure 7. KIF13A Carry M6PR through Interaction with AP-1 negative tail proteins is indicated in red.
(A) Dominant negative KIF13A reduces cell surface M6PR. Four (B) Protein expression profiles of nontransfected (MDCK) and stably
stable MDCK cell lines were produced. GFP line expressing GFP transfected (GFP, clone 2, clone 9, and clone 6) cell lines are shown
(control line), Clones 2 and 9 expressing GFP-KIF13A-tail (this con- as results of Western blotting. An equal number of cells was homog-
tains the AP-1 binding domain), and Clone 6 expressing GFP-KIF1A- enized and resolved by SDS-PAGE followed by Western blotting.
tail. The cell surface expression of M6PR was analyzed by flow (C) Schematic diagram of the involvement of KIF13A in vesicle trans-
cytometry. The vertical axes are the cell count and the horizontal port. The relationship between microtubules (MT), KIF13A, and AP-1
axes are the fluorescent intensity. The left column histograms show complex is shown. m and s represent the minor subunits of the AP-1
the M6PR expression, whereas the right column histograms show complex. We propose that AP-1 binds transmembrane receptors
the GFP expression. In the left column, the green and black histo- (in this case M6PR) on the membrane to KIF13A through interaction
grams are the profiles of the nontransfected cells that were incu- between b1-adaptin ear domain and KIF13A tail domain, thus form-
bated with and without the primary antibody against M6PR, respec- ing a KIF-vesicle binding machinery.
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Conjugation Kit (Pierce) was used. The serum was affinity-purifiedtoskeletons and receptor scaffolding proteins is not un-
with the antigen peptide using a SulfoLink column (Pierce). Other KIFderstood with respect to the function of molecular
antibodies were from Hirokawa lab stocks. Monoclonal antibodiesmotors. It has been shown that M6PR directly interacts
against the b-adaptin clone 100/1 and g-adaptin clone 100/3 were
with the AP-1 complex and enhances the clathrin coat purchased from Sigma. Adaptin antibodies were also purchased
assembly (Robinson and Kreis, 1992; Robinson, 1993). from Transduction Laboratory. Other antibodies were kindly pro-
vided by the researchers acknowledged below.The AP-1 complex is presumed to interact with sorting
signals of other transmembrane receptors as well. The
Purification of b1-Adaptin by GST Pull-Downinteraction between tyrosine-based sorting signals is
Brain high speed supernatant was precleared with glutathione seph-mediated by the m subunit, while dileucine signals may
arose 4B beads and applied to KIF13A-tail-domain bound affinity
interact with the b subunit. columns. The columns were washed extensively followed by elution
Taking the above observations with our data, it is with reduced glutathione. P110 was excised from the gel and was
suggested that during vesicle transport, the transmem- subjected to peptide sequencing at RIKEN. Sucrose velocity gradi-
ent centrifugation of AP-1 was performed as described previouslybrane receptor (M6PR), adaptor protein (AP-1), and mo-
(Duden et al., 1991) except that we used 50 mM Tris-HCl pH8.5, 150lecular motor (KIF13A) can form a complex. Certain pop-
mM NaCl, 1 mM EGTA, and 1 mM Mg-acetate as the basal buffer.ulations of the membrane receptors of transporting
vesicles can be linked to the motor by multiple protein–
GST Pull-Down with b-Adaptin Ear Domain
protein interactions rather than anchored to the vesicles GST-b1-adaptin ear domain (amino acid 700–950) and GST-b2-
by protein–lipid interaction. Our data demonstrate that adaptin ear domain (amino acid 700–938) were expressed in E. coli.
GST pull-downs were performed as above.adaptor proteins on the vesicles (AP-1) interact with the
molecular motor (KIF13A) and function in targeting of
Subcellular Fractionationthe transmembrane receptor (M6PR). Our data raise the
Differential centrifuge method: 3000 3 g supernatant of mouse brainpossibility that such a protein complex that contains a
total homogenate is S1. 15,000 3 g supernatant of S1 is S2. 100,000 3
transmembrane receptor, an adaptor, and a motor may g supernatant of S2 is S3. Nycodenz density gradient method: S2
be a key functional unit for the KIF-dependent intracellu- (1 ml) was mixed with 5 ml of 40% Nycodenz in IMAC. 50% Nycodenz
lar transport, in general. in IMAC (3 ml) at the bottom of the tube was overlaid with 6 ml of
a mixture of sample and 20% Nycodenz in IMAC. Separation was
carried out using an NVT65Ti rotor at 65,000 rpm at 48C for 4 hr.Experimental Procedures
Twenty fractions were collected from the bottom of the tube.
Molecular Biology
Recombinant DNA techniques were performed according to stan- Immunoprecipitation
dard protocols (Okayama et al., 1987; Sambrook et al., 1989). Full- Brain high speed supernatant prepared in IMAC or Triton X-100
length KIF13A cDNA was cloned from a 4-week-old mouse brain extract of P2 fraction was used for immunoprecipitation using Pro-
cDNA library. A 500 bp motor domain probe for KIF13A (Nakagawa tein A Sepharose (Pharmacia) and the antibodies described in the
et al., 1997) was used. PerkinElmer DNA sequencer Model 377 and text.
MacVector 6.5r1 program (Oxford Molecular) were used for se-
quence analysis. Gel Filtratrion
200 ml of the brain high speed supernatant (1.4 mg protein) was
fractionated with Superose-6 HR 10/30 column (Amersham Phar-Production and Purification of the Recombinant Proteins
macia Biotech, AKTA explorer system) in IMAC buffer at a flow rateKIF13A-HC (full length with hexahistidine tag), GST, GST-CTF1
of 0.1 ml/min at 48C.(amino acids 1667 to 1749), and GST-CTF2 (amino acids 1317
to1749) were produced in a baculovirus-insect cell expression sys-
tem. Viruses were produced by standard techniques (O’Reilly et al., Yeast Two-Hybrid Assay
1992). Virus infected cells were homogenized and purified with Ni A yeast two-hybrid assay was performed as described previously
chelating Sepharose FF (Amersham Pharmacia Biotech) or glutathi- (Setou et. al., 2000).
one sepharose (Pharmacia). Virus-infected cells were homogenized
in IMAC buffer (20 mM HEPES pH 7.4, 140 mM potassium-acetate, In Vitro Binding Assay
1 mM magnesium-acetate, 1 mM EGTA, supplemented with protein- GST-b1-adaptin and GST alone (control) were expressed in E. coli
ase inhibitors). and purified as described above. 1 mg of recombinant KIF13A was
incubated with 1 mg of either GST-b1-adaptin or GST, at 48C. Pro-
Taxol-Assisted Microtubule Sedimentation Assay teins were recovered by immunoprecipitating with anti-KIF13A an-
of Various Motors tibody.
Endogenous ATP in 1 ml of brain high speed supernatant was de-
pleted by hexokinase (5 units, Sigma). Purified-bovine-Taxol-stabi- Tissue Cultures and Expression of Wild-Type and Deletion
lized microtubules (0.3 mg) were used. See text for procedures. Mutants of KIF13A in Mammalian Cells
L cells, NRK cells, and MDCKII cells were cultured in high-glucose
Multiple Motor Motility Assays DMEM (Gibco BRL) supplemented with 10% FCS, in MEM (Gibco
The gliding activity of axonemes across KIF13A-coated coverslips BRL) supplemented with 10% FCS, and in DMEM (Gibco BRL) sup-
was observed by standard procedures (Setou et al., 2000). No motil- plemented with 5% FCS, respectively. The cells were incubated at
ity was observed in the preparation from noninfected cells similarly 378C, with 5% CO2. For transfection, PFx perfect lipids (Invitrogen)
processed. and Opti-MEM I (Gibco BRL) were used as reagents. Full-length
KIF13A with a myc epitope tag in the carboxyl terminus, myc tagged
tail-deleted KIF13A construct (amino acid 1–1067), and the full-Antibodies
length KIF1A and KIF5B were expressed in pBOSS. The expressionsAnti-KIF13A polyclonal antibodies were raised in rabbits. Antigen
of all the proteins were confirmed by Western blotting.of antibody 466 was purified recombinant KIF13A-HS. The serum
was affinity-purified with purified GST-CTF2 recombinant fusion
protein conjugated to CNBr-activated Sepharose (Pharmacia Bio- Immunofluorescence Microscopy
For staining, KIF13A cells were fixed with 2% PFA in 0.1 M phos-tech). Antigens of antibody 207 and 397 were synthetic peptide
(CAGNGSPIWEVDSLHAK) and a C-terminal peptide (CLHPKIEND phate buffer (pH 7.5) and permeabilized in 0.2% Triton X-100 in PBS
for 10 min. For staining of g-adaptin, cells were fixed with methanolQEATATR), respectively. Imject Maleimide Activated Immunogen
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at 2208C for 4 min. Blocking was carried out using 5% BSA in PBS. References
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